National Cancer Institute (NCI): Urogenital Neoplasms trials

The registry lists 10 Urogenital Neoplasms studies with National Cancer Institute (NCI) as lead sponsor. 4 are open to participants now and 1 have results posted.

Phase 1 4Phase 2 5No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract MalignanciesRecruitingNCT04923178
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingNCT03866382Phase 2
• Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic CancerRecruitingNCT03412877Phase 2
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerRecruitingNCT01174121Phase 2
• Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous CancerTerminatedNCT03480152Phase 1/2Results posted
• Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic CancerActive, not recruitingNCT06253520Phase 1
• Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary MalignanciesActive, not recruitingNCT04235777Phase 1
• Non-Viral TCR Gene TherapyWithdrawnNCT04102436Phase 2
• Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsActive, not recruitingNCT02496208Phase 1
• Rapid Autopsy and Procurement of Cancer TissueTerminatedNCT01851395